Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices

Biol Blood Marrow Transplant. 2020 Jul;26(7):e147-e160. doi: 10.1016/j.bbmt.2020.04.018. Epub 2020 Apr 24.

Abstract

The full impact of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on the field of hematopoietic cell transplantation (HCT) is unknown. This perspective paper reviews the following: current COVID-19 epidemiology, diagnosis, and potential therapies; care considerations unique to HCT recipients; and the concept of a learning network to assimilate emerging guidelines and best practices and to optimize patient outcomes through facilitating shared learning and experience across transplantation centers.

Keywords: Bone marrow transplantation; COVID-19; Cell therapy; Coronavirus; Hematopoietic cell transplantation; Immunocompromise; SARS-CoV-2; Severe acute respiratory syndrome.

Publication types

  • Review

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity*
  • Bone Marrow Transplantation*
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques / methods
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / therapy
  • Drug Combinations
  • Education, Distance / organization & administration
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Immunization, Passive / methods
  • Infection Control
  • Information Dissemination / methods
  • Lopinavir / therapeutic use
  • Pandemics*
  • Pneumonia, Viral / diagnosis*
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / therapy
  • Practice Guidelines as Topic
  • Real-Time Polymerase Chain Reaction
  • Ritonavir / therapeutic use
  • SARS-CoV-2
  • Severity of Illness Index
  • Tissue Donors / education
  • Tissue Donors / supply & distribution

Substances

  • Drug Combinations
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • remdesivir
  • Adenosine Monophosphate
  • Hydroxychloroquine
  • Ritonavir
  • Alanine

Supplementary concepts

  • COVID-19 serotherapy